Hemochromatosis

by drdoc online

 
 

 

 Hemochromatosis is a disorder of iron metabolism -

It is genetic and as a result there is an accumulation of iron in the tissues - especially in glandular tissue, pancreas and liver, and skin.
The patient becomes bronzy in color from the skin pigment.
The name bronze diabetes is sometimes heard as the patients are often diabetic as well because of iron deposition in the pancreas.

The condition is associated with the development of

1. osteoarthritis of the hips and also interestingly the metacarpal joints of the hands - especially the index and middle fingers.
2. They also develop pseudogout - with deposition of calcium pyrophosphate in the cartilage.

This produces a crystal arthritis and will mimic a type of gout - with flares over days and subsidence over approx 3 wks per attack.

X-rays show calcium deposition in cartilage -

This is seen at the :
Menisci at the knees,
Base of wrist
The shoulder and
Symphisis pubis.

Untreated - osteoarthritis will develop and the joints will deteriorate.

Treatment of the arthritis is with Nonsteroidal antiinflammatories and local cortisone injections into the joints - especially the knees.
Colchicine may also be useful

It is important to treat the underlying iron overload and to screen affected family members.

Genetic testing

Genetic testing for HFE mutations (especially C282Y, H63D, and S65C) is used to confirm hereditary hemochromatosis when iron studies show overload and to screen first‑degree relatives of affected individuals.

What the genetic test looks for:

Most clinical laboratories test the three common HFE variants —

C282Y, H63D, and S65C — which together account for the majority of adult hereditary hemochromatosis cases.
C282Y is the major pathogenic variant, responsible for 85 - 90% of cases in people of Northern European ancestry.
H63D and S65C are milder variants that rarely cause disease on their own

When genetic testing is recommended

Clinical guidelines consistently state that genetic testing should be done only when iron overload is proven or strongly suspected:

Elevated transferrin saturation (>45%)
Elevated serum ferritin (>300 µg/L in males, >200 µg/L in females)
Symptoms or liver abnormalities suggestive of iron overload.

Testing is also recommended for:
Parents, siblings, and adult children of someone with confirmed HFE hemochromatosis
Reproductive partners of individuals with HFE hemochromatosis
General population screening is not recommended because penetrance is incomplete

Interpreting results
Risk depends on genotype:

C282Y/C282Y Highest risk Most likely to develop iron overload, though many never develop symptoms
C282Y/H63D Moderate/low Small increase in risk; often needs cofactors
H63D/H63D Very low Rarely causes disease
Single mutation (carrier) No significant risk May pass variant to children
No mutations No HFE‑related HH Other causes of iron overload must be considered
A positive genetic test does not confirm active disease.

Iron studies are still required to determine whether overload is present

What happens after a positive result

Next steps typically include:
Repeat transferrin saturation and ferritin
Liver assessment (enzymes, MRI/CT if needed)
Referral to a gastroenterologist or hepatologist

Family screening for first degree relatives

Treatment with blood donations- phlebotomy

Phlebotomy is the primary and most effective treatment for hereditary hemochromatosis, removing 400–500 mL of blood per session to lower iron stores

Each unit removes roughly 200–250 mg of iron.
Phase 1: Induction (Iron Depletion)
The goal is to rapidly reduce excess iron.
Frequency:
Weekly or every 2 weeks.
Some patients with very high ferritin may tolerate twice‑weekly sessions.
Volume:400–500 mL per session.
Duration: Several months to >1 year depending on initial ferritin.
Ferritin target: <50 μg/L (international guidelines)
Some guidelines allow 50-100 μg/L as the endpoint.
Monitoring:
Hemoglobin before every session; reduce frequency if <12 g/dL, stop if <11 g/dl.
Ferritin checked monthly or every 4 - 12 sessions.
Phase 2: Maintenance (Lifelong)
Once ferritin reaches target, phlebotomy becomes less frequent.
Frequency:
Every 1-4 months depending on iron reaccumulation.
Ferritin target:
Maintain 50-100 μg/l.
Monitoring:
Ferritin every 6 months.; hemoglobin before each session.
Safety Parameters
Hemoglobin <11 g/dL: stop phlebotomy.
Hemoglobin 11-12 g/dL: reduce frequency or volume.
Avoid excessive depletion --iron deficiency can occur if monitoring is inadequate.
Individual factors influence how often phlebotomy is needed:
Baseline ferritin and transferrin saturation.
Sex (men reaccumulate faster)
Alcohol intake and liver disease.
Genetic modifiers affecting iron absorption
Alternatives When Phlebotomy Is Not Possible
Erythrocytapheresis: fewer sessions per year but higher cost.
Iron chelation: reserved for patients who cannot undergo phlebotomy.
 
 
 
 

Go to diseases page

Go to homepage